References from scientific journals

Dutasteride in Androgenetic Alopecia: An Update.

Arif T, Dorjay K, Adil M, Sami M. Arif T, et al. Curr Clin Pharmacol. 2017;12(1):31-35. doi: 10.2174/1574884712666170310111125. Curr Clin Pharmacol. 2017. PMID: 28294070 Review.

In this review, after the pharmacology of dutasteride, the authors have discussed the status of dutasteride in androgenetic alopecia and have compared its efficacy with that of finasteride. ...Therefore, dutasteride could become a treatment of choice for AGA …
In this review, after the pharmacology of dutasteride, the authors have discussed the status of dutasteride in androgenetic al …

Sexual side effects of 5-alpha-reductase inhibitors finasteride and dutasteride: A comprehensive review.

Fertig RM, Gamret AC, Darwin E, Gaudi S. Fertig RM, et al. Dermatol Online J. 2017 Nov 11;23(11):13030/qt24k8q743. Dermatol Online J. 2017. PMID: 29447628 Free article. Review.

The 5-alpha-reductase inhibitors finasteride and dutasteride are frequently used in the treatment of androgenetic alopecia and benign prostatichyperplasia. ...This review is an extensive look at the sexual effects of 5-alpha-reductase inhibitors and compares outcomes for f …
The 5-alpha-reductase inhibitors finasteride and dutasteride are frequently used in the treatment of androgenetic alopecia and benign …

Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.

Madersbacher S, Sampson N, Culig Z. Madersbacher S, et al. Gerontology. 2019;65(5):458-464. doi: 10.1159/000496289. Epub 2019 Apr 3. Gerontology. 2019. PMID: 30943489 Free article. Review.

Synthesis of dihydrotestosterone is under control of the 5alpha-reductase enzyme, activity of which is antagonized by finasteride and dutasteride. More recently, the impact of prostatic inflammation and metabolic parameters particularly for the development of BPE and LUTS …
Synthesis of dihydrotestosterone is under control of the 5alpha-reductase enzyme, activity of which is antagonized by finasteride and dut …

Female pattern hair loss.

Ioannides D, Lazaridou E. Ioannides D, et al. Curr Probl Dermatol. 2015;47:45-54. doi: 10.1159/000369404. Epub 2015 Feb 20. Curr Probl Dermatol. 2015. PMID: 26370643 Review.


Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.

Lee S, Lee YB, Choe SJ, Lee WS. Lee S, et al. Acta Derm Venereol. 2019 Jan 1;99(1):12-17. doi: 10.2340/00015555-3035. Acta Derm Venereol. 2019. PMID: 30206635 Free article.

The relative risk was 1.66 (95% CI 1.20-2.30) for finasteride and 1.37 (95% CI 0.81-2.32) for dutasteride. Both drugs were associated with an increased risk, although the increase was not statistically significant for dutasteride. As studies into dutasteride …
The relative risk was 1.66 (95% CI 1.20-2.30) for finasteride and 1.37 (95% CI 0.81-2.32) for dutasteride. Both drugs were associated …

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version.

Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A, Trakatelli M, Tosti A, Del Marmol V, Piraccini BM, Nast A, Blume-Peytavi U. Kanti V, et al. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):11-22. doi: 10.1111/jdv.14624. Epub 2017 Nov 27. J Eur Acad Dermatol Venereol. 2018. PMID: 29178529


Androgens in women: Hormone-modulating therapies for skin disease.

Azarchi S, Bienenfeld A, Lo Sicco K, Marchbein S, Shapiro J, Nagler AR. Azarchi S, et al. J Am Acad Dermatol. 2019 Jun;80(6):1509-1521. doi: 10.1016/j.jaad.2018.08.061. Epub 2018 Oct 10. J Am Acad Dermatol. 2019. PMID: 30312645 Review.

In the second article in this Continuing Medical Education series, we discuss the hormone-modulating therapies available to dermatologists for the treatment of AMCDs, including combined oral contraceptives, spironolactone, finasteride, dutasteride, and flutamide. Available …
In the second article in this Continuing Medical Education series, we discuss the hormone-modulating therapies available to dermatologists f …

Physiology and Medical Treatments for Alopecia.

Tai T, Kochhar A. Tai T, et al. Facial Plast Surg Clin North Am. 2020 May;28(2):149-159. doi: 10.1016/j.fsc.2020.01.004. Facial Plast Surg Clin North Am. 2020. PMID: 32312501 Review.


RF-Mesotherapy With Dutasteride: A Future Alternative Treatment for Androgenetic Alopecia.

Reguero-Del Cura L, Durán-Vian C, de Quintana-Sancho A. Reguero-Del Cura L, et al. Actas Dermosifiliogr (Engl Ed). 2020 Jun;111(5):419-420. doi: 10.1016/j.ad.2018.10.030. Epub 2020 May 13. Actas Dermosifiliogr (Engl Ed). 2020. PMID: 32416936 Free article. English, Spanish. No abstract available.


Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss, 2017 version.

Manabe M, Tsuboi R, Itami S, Osada SI, Amoh Y, Ito T, Inui S, Ueki R, Ohyama M, Kurata S, Kono T, Saito N, Sato A, Shimomura Y, Nakamura M, Narusawa H, Yamazaki M; Drafting Committee for the Guidelines for the Diagnosis and Treatment of Male- and Female-Pattern Hair Loss. Manabe M, et al. J Dermatol. 2018 Sep;45(9):1031-1043. doi: 10.1111/1346-8138.14470. Epub 2018 Jun 4. J Dermatol. 2018. PMID: 29863806

Thus, here we report a revised version of the 2010 guidelines aimed at both MPHL and FPHL. In these guidelines, finasteride 1 mg daily, dutasteride 0.5 mg daily and topical 5% minoxidil twice daily for MPHL, and topical 1% minoxidil twice daily for FPHL, are recommended as …
Thus, here we report a revised version of the 2010 guidelines aimed at both MPHL and FPHL. In these guidelines, finasteride 1 mg daily, d …